Glenmark's North America API business is based out of Mahwah, New Jersey and caters to the US and Canada markets. This business additionally supports its customers for first-to-file opportunities in these markets with its dedicated IP and regulatory teams. It is the main region for most of the new API development and patent filings at Glenmark.
Glenmark’s European API business has a robust portfolio of over 100 products developed by our dedicated R&D team. The product portfolio constitutes of a mix of over 18 APIs with CEPs, 40 APIs which are commercially available along with DMF and more than 40 others in various stages of development. Our customer base includes key global generic companies, pan-European generic companies, national generic companies, contract manufacturers and dossier developers.
The API team in Latin America is based in São Paulo, Brazil. This business has been growing consistently over the years, with a focus on all Latin American markets complying with the regulatory guidelines of ANVISA in Brazil and COFEPRIS in Mexico. Glenmark maintains its market leadership position for Bupropion, Cilostazol and Olmesartan in Latin America.
Glenmark has increased its focus on the Japan API market. As a first step towards our entry into the world’s second biggest market, we have acquired an Accreditation of Foreign Manufacturer (AFM) for the Ankleshwar API manufacturing facility.
We filed our first J-DMF in 2011 and are targeting to enhance our J-DMF portfolio. In addition to this, all our focused products for Japan are screened to check the suitability to meet the Japanese Pharmacopeial requirements and high purity standards.
Rest of the world
Glenmark’s API business has a reach in more than 20 countries in the semi-regulated markets of Asia, Middle East, Africa & CIS, with market leadership in several products including Perindopril, Glimepiride, Etoricoxib & Desloratadine.
The company also has a strong presence in markets such as South Korea, Russia, South Africa & China and is registering new products and catering to the API requirements of major pharmaceutical companies and MNCs in this region.
Glenmark has been operating in the Indian market since its inception in 1977. We are a leading player in India, with a robust portfolio of branded generic products. Since our inception, Glenmark has launched over 320 products in the Indian market. We have consistently been ranked among the Top 20 fastest growing companies in the Indian Pharmaceutical Market. In our key therapy categories in India, we ranked second in dermatology, sixth in respiratory and ninth in cardiovascular.
Glenmark’s strategy has been to capitalize on the first-mover advantage by making an early entry to new high-growth therapy segments, which is driven by developing strong brands across core therapy categories, and the introduction of new products on a regular basis. In India, our branded formulations business focuses on high growth and large therapy categories such as dermatology, respiratory, cardiovascular, anti-diabetic and oncology. We are also present in some of the other therapy categories such as gynecology, anti-infective and gastroenterology. To strengthen our branded formulations business in India, we have organized our branded formulations business into multiple divisions which focus on select therapy categories with a team of more than 3,700 medical marketing representatives.